What the conversation covers Unique challenges in type 1 diabetes , why insulin alone has structural limitations The mechanism , how GLP-1 therapies work The evidence in type 1 diabetes , from early studies to ADJUST T1D and tirzepatide Exploration points , what the evidence tends to show on insulin adjustment, monitoring, and nutrition Future directions , triple and quadruple agonists, reimbursement, and paediatric potential Watch or listen Key themes Why insulin alone has structural limitations The episode opens by exploring why insulin alone has structural limitations in type 1 diabetes
Accurate dosing depends on accurate measuring, and simpler math means fewer errors
Importantly, such modifications precisely regulate protein structure and function 22,23
The FDA issued its own warning about compounded semaglutide in May, stating its received reports of adverse events following the use of compounded versions of the drug, and warned that patients shouldnt use a compounded drug if an approved drug is available
Common low igf-1 symptoms include reduced muscle mass, low energy, and subtle mood changes
